Targeting IL-23 a Hit in Psoriatic Arthritis

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Not that this randomized trial of the anti-Il23 antibody guselkumab for the treatment of psoriatic arthritis found strong evidence of efficacy across many outcome metrics.
  • Overall, the novel medication appeared to be well-tolerated.

MADRID — The anti-interleukin (IL)-23 monoclonal antibody guselkumab was effective in relieving multiple disease domains of psoriatic arthritis, a phase IIa study found.

In a cohort of 149 patients with active disease, the primary endpoint — a 20% response according to the criteria of the American College of Rheumatology (ACR20) — was achieved at week 24 by 58% of those receiving guselkumab compared with 18.4% of those given placebo (P<0.001), according to Atul Deodhar, MD, of Oregon Health & Science University in Portland.

In addition, 78.6% of those receiving guselkumab had 75% improvement on the Psoriasis Area and Severity Index (PASI75) compared with 12.5% of those on placebo (P<0.001), he reported at the annual European Congress of Rheumatology here.

“Guselkumab targets the p19 subunit of IL-23, whereas IL-12 and IL-23 share the p40 subunit, which is blocked by ustekinumab (Stelara). Guselkumab has previously demonstrated efficacy in three phase III trials,” Deodhar said at the meeting.

“This agent is completely new, and opens up…

Read the full article from the Source…

Back to Top